LFCR

Lifecore Biomedical's stock price has significantly declined over the past six months, decreasing by 43.40% to $4.46 as of September 18, 2026, from $7.88 on September 22, 2025. It also saw a 45.97% decrease over the last 12 months, an 8.37% decrease in the past month, and a 49.14% year-to-date decrease. Key events include Q1 2026 financial results, reported on May 6, 2026, showing revenues of $23.2 million (a 34% decrease) and a net loss of $15.0 million, though guidance was reaffirmed. Q2 2026 financial results, reported on August 5, 2026, showed revenue of $34.2 million (down 6.2%), with CDMO revenue falling 34% while HA manufacturing grew 44%, and a widened net loss of $6.2 million, with guidance and long-term goals reaffirmed. The company signed three new commercial site transfer programs in Q1 2026 and successfully launched a new ERP system in January 2026, expected to improve inventory control, financial management, and cost reduction. In September 2026, Lifecore announced a new agreement to transfer a commercially marketed product. Capital structure concerns, particularly a debt overhang, have been identified as a key risk and potential stock catalyst.